Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
RecombinantRabMAb

Recombinant Anti-IL-6 antibody [EPR23819-11] (ab259341)

Submit a review Submit a question
Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
  • Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)
  • Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
  • Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)
  • Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
  • Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)
  • Anti-IL-6 antibody [EPR23819-11] (ab259341)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR23819-11] to IL-6
  • Suitable for: WB, IP
  • Reacts with: Mouse, Rat, Human

Conjugates logo Related conjugates and formulations

Carrier Free

Overview

  • Product name

    Anti-IL-6 antibody [EPR23819-11]
    See all IL-6 primary antibodies

  • Description

    Rabbit monoclonal [EPR23819-11] to IL-6

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IPmore details
    Unsuitable for: Flow Cyt (Intra),ICC/IF,IHC or IHC-Fr

  • Species reactivity

    Reacts with: Mouse, Rat, Human

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: RAW264.7 treated with 0.1 µg/ml lipopolysaccharide (LPS) then with 1 µg/ml Brefeldin A (BFA), HUVEC treated with 0.5 µg/ml LPS, then with 0.3 µg/ml BFA, NR8383 treated with 0.1 µg/ml LPS, then with 1 µg/ml BFA IP: RAW264.7 treated with 0.1 µg/ml LPS, then with 1ug/ml BFA, HUVEC treated with 0.5 ug/ml LPS, then with 0.3 µg/ml BFA, NR8383 cells treated with 0.1 µg/ml LPS, then with 1 ug/ml BFA.

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab259341 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
1/1000. Predicted molecular weight: 23 kDa.
IP
1/30.
Notes
WB
1/1000. Predicted molecular weight: 23 kDa.
IP
1/30.
Application notes
Is unsuitable for Flow Cyt (Intra),ICC/IF,IHC or IHC-Fr.

Target

  • Function

    Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.

  • Involvement in disease

    Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
    Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.

  • Sequence similarities

    Belongs to the IL-6 superfamily.

  • Post-translational
    modifications

    N- and O-glycosylated.

  • Cellular localization

    Secreted.
  • Information by UniProt

  • Database links

    see all

  • Alternative names

    • Interleukin BSF 2 antibody
    • B cell differentiation factor antibody
    • B cell stimulatory factor 2 antibody
    • B-cell stimulatory factor 2 antibody
    • BSF 2 antibody
    • BSF-2 antibody
    • BSF2 antibody
    • CDF antibody
    • CTL differentiation factor antibody
    • Cytotoxic T cell differentiation factor antibody
    • Hepatocyte stimulating factor antibody
    • Hepatocyte stimulatory factor antibody
    • HGF antibody
    • HSF antibody
    • Hybridoma growth factor antibody
    • Hybridoma growth factor Interferon beta-2 antibody
    • Hybridoma plasmacytoma growth factor antibody
    • IFN-beta-2 antibody
    • IFNB2 antibody
    • IL 6 antibody
    • IL-6 antibody
    • IL6 antibody
    • IL6_HUMAN antibody
    • Interferon beta 2 antibody
    • Interferon beta-2 antibody
    • Interleukin 6 antibody
    • Interleukin 6 (interferon beta 2) antibody
    • Interleukin BSF 2 antibody
    • Interleukin-6 antibody
    see all

Images

  • Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    All lanes : Anti-IL-6 antibody [EPR23819-11] (ab259341) at 1/1000 dilution

    Lane 1 : Untreated RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate
    Lane 2 : RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 0.1 µg/ml lipopolysaccharide (LPS) for 4 hours, then with 1 µg/ml Brefeldin A (BFA) added for 3 hours whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)

    Predicted band size: 23 kDa
    Observed band size: 24 kDa why is the actual band size different from the predicted?



    Blocking and diluting buffer and concentration: 5% NFDM/TBST. The molecular weight is consistent with what has been described in the literatures (PMID:2523818, PMID:25130514)

    IL6 expressed in LPS-induced RAW264.7 cells (PMID:31718640, PMID:30823686).

    Exposure time: 26 seconds

     

  • Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)

    IL-6 was immunoprecipitated from 0.35 mg HUVEC (human umbilical vein endothelial cell) treated with 0.5 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 0.3 ug/ml Brefeldin A (BFA) added for 20 hours whole cell lysate 10 ug with ab259341 at 1/30 dilution (2 ug in 0.35 mg lysates). Western blot was performed on the immunoprecipitate using ab259341 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.

    Lane 1: HUVEC (human umbilical vein endothelial cell) treated with 0.5 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 0.3 ug/ml Brefeldin A (BFA) added for 20 hours whole cell lysate 10 ug

    Lane 2: ab259341 IP in HUVEC treated with 0.5 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 0.3 ug/ml Brefeldin A (BFA) added for 20 hours whole cell lysate

    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab259341 in HUVEC treated with 0.5 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 0.3 ug/ml Brefeldin A (BFA) added for 20 hours whole cell lysate

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 3 minutes

     

  • Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    All lanes : Anti-IL-6 antibody [EPR23819-11] (ab259341) at 1/1000 dilution

    Lane 1 : Untreated HUVEC (human umbilical vein endothelial cell) whole cell lysate
    Lane 2 : HUVEC (human umbilical vein endothelial cell) treated with 0.5 µg/ml lipopolysaccharide (LPS) for 4 hours, then with 0.3 µg/ml Brefeldin A (BFA) added for 20 hours whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Predicted band size: 23 kDa
    Observed band size: 20 kDa why is the actual band size different from the predicted?



    Blocking and diluting buffer and concentration: 5% NFDM/TBST. The molecular weight is consistent with what has been described in the literatures (PMID:2523818, PMID:25130514)

    Exposure time: 3 minutes

     

  • Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)

    IL-6 was immunoprecipitated from 0.35 mg RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 0.1 µg/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate 10 ug with ab259341 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab259341 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.

    Lane 1: RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) treated with 0.1 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate 10 ug

    Lane 2: ab259341 IP in RAW264.7 treated with 0.1ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate

    Lane 3:Rabbit monoclonal IgG (ab172730) instead of ab259341 in RAW264.7 treated with 0.1ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 3 minutes

     

  • Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    Western blot - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    All lanes : Anti-IL-6 antibody [EPR23819-11] (ab259341) at 1/1000 dilution

    Lane 1 : Untreated NR8383 (rat lung macrophage (alveolar)) whole cell lysate
    Lane 2 : NR8383 (rat lung macrophage (alveolar)) treated with 0.1 µg/ml lipopolysaccharide (LPS) for 4 hours, then with 1 µg/ml Brefeldin A (BFA) added for 3 hours whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)

    Predicted band size: 23 kDa
    Observed band size: 20 kDa why is the actual band size different from the predicted?



    Blocking and diluting buffer and concentration: 5% NFDM/TBST. This blot was developed using a higher sensitivity ECL substrate.

    The molecular weight is consistent with what has been described in the literatures (PMID:2523818, PMID:25130514)

    Exposure time: 3 minutes

     

  • Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)
    Immunoprecipitation - Anti-IL-6 antibody [EPR23819-11] (ab259341)

    IL-6 was immunoprecipitated from 0.35 mg NR8383 (rat lung macrophage (alveolar)) treated with 0.1 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate 10 ug with ab259341 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab259341 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.

    Lane 1: NR8383 (rat lung macrophage (alveolar)) treated with 0.1 ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate 10 ug

    Lane 2: ab259341 IP in NR8383 treated with 0.1ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate

    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab259341 in NR8383 treated with 0.1ug/ml lipopolysaccharide (LPS) for 4 hours, then with 1 ug/ml Brefeldin A (BFA) added for 3 hours whole cell lysate

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 3 minutes

     

  • Anti-IL-6 antibody [EPR23819-11] (ab259341)
    Anti-IL-6 antibody [EPR23819-11] (ab259341)

Protocols

To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

Click here to view the general protocols

References (0)

Publishing research using ab259341? Please let us know so that we can cite the reference in this datasheet.

ab259341 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab259341.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com